Dotarem approved for nervous system MRIs

March 21, 2013

(HealthDay)—Dotarem (gadoterate meglumine) has been approved by the U.S. Food and Drug Administration as a contrast agent for use in MRIs of the brain, spine and other parts of the central nervous system.

Approved for people two years and older, the imaging agent helps radiologists detect lesions and other abnormalities. Dotarem and similar agents all carry a boxed label warning of the risk of nephrogenic systemic fibrosis, a rare yet dangerous condition that can develop in people with kidney disease, the FDA said in a news release. The condition is characterized by pain and thickening of the skin.

Dotarem's safety and effectiveness were evaluated in clinical studies involving 245 adults and 38 children with suspected abnormalities of the . All side effects were rare, the agency said, but the most common ones included nausea, headache, a , and injection-site pain and coldness.

Dotarem is marketed by Guerbet LLC, based in Bloomington, Ind.

Explore further: Marqibo approved for ph- acute lymphoblastic leukemia

More information: The FDA has more about this approval.

Related Stories

Marqibo approved for ph- acute lymphoblastic leukemia

August 10, 2012

(HealthDay) -- Marqibo (vincristine sulfate liposome injection) has been approved by the U.S. Food and Drug Administration to treat adults with Philadelphia chromosome negative acute lymphoblastic leukemia (ALL).

Marqibo approved for rare leukemia

August 10, 2012

(HealthDay) -- Marqibo (vincristine sulfate liposome injection) has been approved by the U.S. Food and Drug Administration to treat adults with a rare form of blood and bone marrow cancer, Philadelphia chromosome negative ...

Cometriq approved for rare thyroid cancer

November 29, 2012

(HealthDay)—Cometriq (cabozantinib) has been approved by the U.S. Food and Drug Administration to treat modullary thyroid cancer that has spread to other parts of the body, the agency said Thursday.

Iclusig approved for rare leukemias

December 16, 2012

(HealthDay)—Iclusig (ponatinib) has been approved by the U.S. Food and Drug Administration to treat two rare forms of leukemia..

Gattex approved for short bowel syndrome

December 22, 2012

(HealthDay)—Gattex (teduglutide) has been approved by the U.S. Food and Drug Administration to treat nutritional problems caused by short bowel syndrome.

Drug OK'd for deadly genetic condition tied to cholesterol

January 30, 2013

(HealthDay)—Kynamro (mipomersen sodium) has been approved by the U.S. Food and Drug Administration to treat a rare inherited condition in which the body can't remove low-density lipoprotein (LDL) cholesterol from the blood.

Recommended for you

Treatment options for opioid addiction are expanding

August 10, 2016

In the past two decades, the devastation associated with opioid addiction has escaped the relative confines of the inner city and extended to suburban and rural America. Due in large part to the proliferation of prescription ...

Can exercise be replaced with a pill?

October 2, 2015

Everyone knows that exercise improves health, and ongoing research continues to uncover increasingly detailed information on its benefits for metabolism, circulation, and improved functioning of organs such as the heart, ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.